Compare Marathon Petroleum Corp (MPC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Marathon Petroleum Corp trades at $484.92 (market cap $133.95B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Marathon Petroleum Corp is far larger — about 17.8× Spyre Therapeutics Inc. Common Stock's market cap, and Marathon Petroleum Corp pays a 0.84% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 53 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MPC | SYRE | |
|---|---|---|
Market Cap | $133.95B | $7.52B |
Volume | 1,644,329 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $484.92 | $108.92 |
52-Week Low | $162.63 | $22.18 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $160.47B | $6.52B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $484.92, up 5.69% today, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a reasonable P/E of 16.54. Recent news highlights refining margin strength and positive analyst sentiment, though it faces risks from potential diesel export policy shifts.
The outlook remains positive given tight refining markets and earnings growth projections, but investors should weigh policy risks and high debt levels. Wall Street consensus is strongly bullish with a $444.30 price target, though the current price exceeds this, suggesting near-term caution may be warranted despite long-term fundamentals.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
